Her-2/neu peptide vaccine: Phase I

CRXA said that an immune response was induced to the protein in 16 of 22 patients who completed treatment with its Her-2/neu vaccine. Efficacy was not evaluated. Toxicities were hives and muscle aches. To date, 51 patients have entered the U.S. Phase I trial. Findings were reported at the American Society of Clinical Oncology meeting in Los Angeles. ...